Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSC with Radiation and Temozolomide in Newly Diagnosed Glioblastoma
NCT01465347Phase 2Completed
- Sponsor
- Diffusion Pharmaceuticals Inc.
- Start
- Feb 2012
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trans sodium crocetinate in glioblastoma (GBM), sponsored by Diffusion Pharmaceuticals Inc.. Started Feb 2012; status: completed.
02
Drugs
trans sodium crocetinate
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01465347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01465347.